184 related articles for article (PubMed ID: 37735346)
1. SAEM GRACE: Anti-craving medications for alcohol use disorder treatment in the emergency department: A systematic review of direct evidence.
Punia K; Scott W; Manuja K; Sabbineni M; Campbell K; Balodis IM; MacKillop J
Acad Emerg Med; 2024 May; 31(5):504-514. PubMed ID: 37735346
[TBL] [Abstract][Full Text] [Related]
2. Baclofen for alcohol use disorder.
Agabio R; Saulle R; Rösner S; Minozzi S
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012557. PubMed ID: 36637087
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological treatment of alcohol dependence: a review of the evidence.
Garbutt JC; West SL; Carey TS; Lohr KN; Crews FT
JAMA; 1999 Apr; 281(14):1318-25. PubMed ID: 10208148
[TBL] [Abstract][Full Text] [Related]
4. Baclofen for alcohol use disorder.
Minozzi S; Saulle R; Rösner S
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012557. PubMed ID: 30484285
[TBL] [Abstract][Full Text] [Related]
5. Guidelines for Reasonable and Appropriate Care in the Emergency Department (GRACE-4): Alcohol use disorder and cannabinoid hyperemesis syndrome management in the emergency department.
Borgundvaag B; Bellolio F; Miles I; Schwarz ES; Sharif S; Su MK; Baumgartner K; Liss DB; Sheikh H; Vogel J; Austin EB; Upadhye S; Klaiman M; Vellend R; Munkley A; Carpenter CR
Acad Emerg Med; 2024 May; 31(5):425-455. PubMed ID: 38747203
[TBL] [Abstract][Full Text] [Related]
6. Adherence Across FDA-Approved Medications for Alcohol Use Disorder in a Veterans Administration Population.
Walker JR; Korte JE; McRae-Clark AL; Hartwell KJ
J Stud Alcohol Drugs; 2019 Sep; 80(5):572-577. PubMed ID: 31603760
[TBL] [Abstract][Full Text] [Related]
7. Implementation of Oral and Extended-Release Naltrexone for the Treatment of Emergency Department Patients With Moderate to Severe Alcohol Use Disorder: Feasibility and Initial Outcomes.
Anderson ES; Chamberlin M; Zuluaga M; Ullal M; Hawk K; McCormack R; D'Onofrio G; Herring AA
Ann Emerg Med; 2021 Dec; 78(6):752-758. PubMed ID: 34353648
[TBL] [Abstract][Full Text] [Related]
8. Comparison of healthcare utilization among patients treated with alcoholism medications.
Mark TL; Montejano LB; Kranzler HR; Chalk M; Gastfriend DR
Am J Manag Care; 2010; 16(12):879-88. PubMed ID: 21348558
[TBL] [Abstract][Full Text] [Related]
9. Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial.
Collins SE; Duncan MH; Saxon AJ; Taylor EM; Mayberry N; Merrill JO; Hoffmann GE; Clifasefi SL; Ries RK
Lancet Psychiatry; 2021 Apr; 8(4):287-300. PubMed ID: 33713622
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.
Kranzler HR; Soyka M
JAMA; 2018 Aug; 320(8):815-824. PubMed ID: 30167705
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
Donoghue K; Elzerbi C; Saunders R; Whittington C; Pilling S; Drummond C
Addiction; 2015 Jun; 110(6):920-30. PubMed ID: 25664494
[TBL] [Abstract][Full Text] [Related]
12. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.
Williams EC; Matson TE; Harris AHS
Addict Sci Clin Pract; 2019 Feb; 14(1):6. PubMed ID: 30744686
[TBL] [Abstract][Full Text] [Related]
13. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
[TBL] [Abstract][Full Text] [Related]
14. Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review.
Hyland CJ; McDowell MJ; Bain PA; Huskamp HA; Busch AB
J Subst Abuse Treat; 2023 Jan; 144():108919. PubMed ID: 36332528
[TBL] [Abstract][Full Text] [Related]
15. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
[TBL] [Abstract][Full Text] [Related]
16. Implementation and analysis of a multifaceted intervention for alcohol use disorder from a single academic urban emergency department.
Duvalyan E; Falade I; Fan W; Foe M; Mvemba A; Zussman JW; Geier C; LeSaint KT; Graglia S
Acad Emerg Med; 2024 May; 31(5):456-462. PubMed ID: 38380769
[TBL] [Abstract][Full Text] [Related]
17. Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.
Qeadan F; Mensah NA; Gu LY; Madden EF; Venner KL; English K
Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444639
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.
Heikkinen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J
Addiction; 2021 Aug; 116(8):1990-1998. PubMed ID: 33394527
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
Maisel NC; Blodgett JC; Wilbourne PL; Humphreys K; Finney JW
Addiction; 2013 Feb; 108(2):275-93. PubMed ID: 23075288
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.
McPheeters M; O'Connor EA; Riley S; Kennedy SM; Voisin C; Kuznacic K; Coffey CP; Edlund MD; Bobashev G; Jonas DE
JAMA; 2023 Nov; 330(17):1653-1665. PubMed ID: 37934220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
